Catechins as a Potential Dietary Supplementation in Prevention of Comorbidities Linked with Down Syndrome.

Christophe Noll, Janany Kandiah, Gautier Moroy, Yuchen Gu, Julien Dairou, Nathalie Janel

Journal: Nutrients 2022;14(10):2039

PMID: 35631180

Abstract

Plant-derived polyphenols flavonoids are increasingly being recognized for their medicinal potential. These bioactive compounds derived from plants are gaining more interest in ameliorating adverse health risks because of their low toxicity and few side effects. Among them, therapeutic approaches demonstrated the efficacy of catechins, a major group of flavonoids, in reverting several aspects of Down syndrome, the most common genomic disorder that causes intellectual disability. Down syndrome is characterized by increased incidence of developing Alzheimer's disease, obesity, and subsequent metabolic disorders. In this focused review, we examine the main effects of catechins on comorbidities linked with Down syndrome. We also provide evidence of catechin effects on DYRK1A, a dosage-sensitive gene encoding a protein kinase involved in brain defects and metabolic disease associated with Down syndrome.

Address: Division of Endocrinology, Department of Medicine, Centre de Recherche du CHUS, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.; Unité de Biologie Fonctionnelle et Adaptative, UMR 8251 CNRS, Université Paris Cité, F-75013 Paris, France.; Unité de Biologie Fonctionnelle et Adaptative, INSERM CNRS, Université Paris Cité, F-75013 Paris, France.; Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, UMR 8601 CNRS, Université Paris Cité, F-75006 Paris, France.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.